Prestige Consumer Healthcare, Inc. (PBH)
46.19
+0.87
(+1.92%)
USD |
NYSE |
Nov 13, 16:00
46.16
-0.04
(-0.08%)
After-Hours: 19:59
Prestige Consumer Healthcare EPS Diluted (Quarterly) : 0.5315 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.5315 |
| June 30, 2026 | 0.6129 |
| March 31, 2026 | 1.131 |
| December 31, 2025 | 0.9711 |
| September 30, 2025 | 0.8568 |
| June 30, 2025 | 0.9525 |
| March 31, 2025 | 1.001 |
| December 31, 2024 | 1.221 |
| September 30, 2024 | 1.088 |
| June 30, 2024 | 0.9762 |
| March 31, 2024 | 0.9831 |
| December 31, 2023 | 1.058 |
| September 30, 2023 | 1.069 |
| June 30, 2023 | 1.061 |
| March 31, 2023 | -4.831 |
| December 31, 2022 | 1.035 |
| September 30, 2022 | 1.015 |
| June 30, 2022 | 1.090 |
| March 31, 2022 | 1.022 |
| December 31, 2021 | 0.9859 |
| September 30, 2021 | 0.8924 |
| June 30, 2021 | 1.140 |
| March 31, 2021 | 0.7031 |
| December 31, 2020 | 0.8084 |
| September 30, 2020 | 0.8801 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.8602 |
| March 31, 2020 | 0.7281 |
| December 31, 2019 | 0.7487 |
| September 30, 2019 | 0.6544 |
| June 30, 2019 | 0.6518 |
| March 31, 2019 | -2.683 |
| December 31, 2018 | 0.7311 |
| September 30, 2018 | 0.5914 |
| June 30, 2018 | 0.65 |
| March 31, 2018 | -0.747 |
| December 31, 2017 | 5.88 |
| September 30, 2017 | 0.5735 |
| June 30, 2017 | 0.63 |
| March 31, 2017 | 0.21 |
| December 31, 2016 | 0.59 |
| September 30, 2016 | 0.60 |
| June 30, 2016 | -0.10 |
| March 31, 2016 | 0.26 |
| December 31, 2015 | 0.53 |
| September 30, 2015 | 0.60 |
| June 30, 2015 | 0.49 |
| March 31, 2015 | 0.45 |
| December 31, 2014 | 0.40 |
| September 30, 2014 | 0.31 |
| June 30, 2014 | 0.32 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 0.3516 |
| Phibro Animal Health Corp. | 0.7208 |
| Structure Therapeutics, Inc. | -1.992 |
| ANI Pharmaceuticals, Inc. | 1.510 |
| Corcept Therapeutics, Inc. | 1.010 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 25.30M |
| Revenue (Quarterly) | 336.31M |
| Total Expenses (Quarterly) | 311.01M |
| Enterprise Value | 4.270B |
| Gross Profit Margin (Quarterly) | 48.71% |
| Profit Margin (Quarterly) | 7.52% |
| Earnings Yield | 7.03% |
| Operating Earnings Yield | 13.21% |
| Normalized Earnings Yield | 7.072 |